References
Anon. Facing the recruitment and retention crisis in pharmacy: looking abroad. Pharm J 2001; 276: 45–46.
Cousins D, Luscombe D. Forces for change and the evolution of clinical pharmacy practice. Pharm J 1995; 255: 771–776.
Dosaj R, Mistry R. The pharmacy technician in clinical services. Hosp Pharm 1998; 5(1): 26–28.
Dhillon S, Duggan C, Pearsall K, et al. An evaluation of interventions of a major significance in North West Thames. CPD Pharmacy 2000; 1: 12–18.
References
Liebelt E L, DeAngelis C D. Evolving Trends and Treatment Advances in Pediatric Poisoning. Journal of the American Medical Association 1999; 282 (12): 1113–1115.
Shannon M. Ingestion of Toxic Substances by Children. New England Journal of Medicine 2000; 342: 186–191.
Breitigan J M. Protecting children in the community from poisons. American Journal of Health-System Pharmacy 1998; 55: 1971–1973.
Ernest S, Stremski M D. Accidental Pediatric Ingestion, Hospital Charges and Failure to Utilize a Poison Control Center. Wisconsin Medical Journal 1999; 29–33.
Information from the National Poisons Information Service. CMO's Update – a communication to all doctors from the Chief Medical Officer, Department of Health. 2000; 25: 3.
Personal Communication with Alison Dines, London Poisons Unit, May 2000.
Tempowski J. Epidemiology of Poisoning in Children from Paediatric Toxicology: Handbook of Poisoning in Children 1997 edited by N Bates, N Edwards, J Roper, G Volans. Publ. Macmillan Reference Ltd.
References
Cancer in Scotland Action for Change. Scottish Executive. 2001.
Cancer Scenarios: an aid to planning cancer services in Scotland in the next decade. Scottish Executive. May 2001.
Booth CD. Pharmacist-managed anticoagulant clinics: a review. Pharm J 1998; 261: 623–625.
Bozovich M et al. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education programme low-density lipoprotein goals. Pharmacotherapy 2000; 20(11): 1375–1383.
Bonadonna G, Valagussa P. Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer. NEJM. 1981; 304: 10–15.
References
Blenkinsopp, A., Tann, J and Platts, A. A method for distinguishing leading edge practitioners – a case study in community pharmacy. Journal of social and administrative pharmacy 1999; 16(3/4): 186–197.
. Tann, J., Blenkinsopp, A., Allen, J. and Platts, A. Leading edge practitioners in community pharmacy: approaches to innovation. International Journal of Pharmacy Practice 1996; 4(4): 235–245.
References
Anon. Which NSAID? Drug Ther Bull 1987; 25: 81–84.
National Institute for Clinical Excellence (NICE) guidance on the use of cyclo-oxygenase (COX)-II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. July 2001, Technology Appraisal Guidance No. 27. www.nice.org.uk
Brooks P, Emery P, Evans JF et al. Interpreting the clinical significance of the differential inhibition of COX-1 and COX-2. Rheumatol (Oxford) 1999; 38: 779–88.
Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis (VIGOR study). N Engl J Med 2000; 343: 1520–28.
Silverstein FE, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis: the CLASS study-a randomised controlled trial. JAMA 2000; 284: 1247–55.
References
World Health Organisation (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO.
National Service Framework for Older People. London: Department of Health; March 2001.
Royal College of Physicians. Osteoporosis. Clinical guidelines for prevention and treatment. London: The College; 1999.
American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatism 1996; 39: 1791–1801.
Gennari C, Martini G, Nuti R. Secondary osteoporosis. Ageing (milano) 1998; 10: 214–24.
Eastell R, Reid DM, et al. A UK consensus group management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271–292.
van Staa TP, Leufkens HGM, et al. Oral corticosteroids and fracture risk:-relationship to daily and cumulative doses. Rheum 2000; 39: 1383–9.
Osteoporosis. Prevention, diagnosis and therapy. NIH Consensus Statement Online 2000 March 27–29; 17: 1–36.
Feldkamp J, Becker A, White O, et al. Long term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast like cells. Exp Clin Endocrin Diabetes 2000; 108: 37–43.
References
Scottish Office. Scotland's Health: a challenge to us all. Edinburgh: HMSO, 1992.
2. Lanarkshire Primary Care NHS Trust Clinical Governance Report Year 2 2001.
Scottish Office Department of Health. Scotland's Health: Scottish Health Survey 1998. Edinburgh: The Stationery Office; 2000.
Joint British recommendations on prevention of coronary heart disease in clinical practice. BMJ Publishing Group Supplement 2 December 1998 Vol. 80.
World Health Organisation (Europe) and International Diabetes Federation (Europe). Diabetes Care and Research in Europe; the St Vincent Declaration Diab.et Med. 1990; 7: 360–370.
References
NHS Executive. The NHS Plan, 2000.
NHS Executive. Pharmacy in the Future – implementing the NHS Plan; A programme for pharmacy in the National Health Service, 2000.
Royal Pharmaceutical Society of Great Britain. Medicines and Ethics Guide for Pharmacists. Pharmaceutical Press, 2000.
Whiddett, S. and Hollyford, S. (2000) The Competencies Handbook. 1st ed, London, Institute of Personnel and Development, 2000.
Miller, GE. The assessment of clinical skills/competence/performance. Acad Med 1990, 65 563–67.
McRobbie, D. & Davies, G. (1996) Assessing clinical competence – a new method of evaluating hospital pre-registration trainees. Pharmaceutical Journal, 256 908–910.
Rights and permissions
About this article
Cite this article
Progress in Practice; UKCPA Residential Symposium, Hilton Hotel, Manchester, UK. Friday, 17-Sunday, 19 May 2002. Pharm World Sci 25, 37–50 (2003). https://doi.org/10.1023/A:1022432901285
Issue Date:
DOI: https://doi.org/10.1023/A:1022432901285